MED18

Across TCGA pan-cancer cohorts, MED18 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MED18’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MED18 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MED18 is over-expressed in tumor.

HNSC, LSCC, and LUAD are the cancer types where MED18 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MED18 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.461	<.001	11	view →
LSCC	Male	All	+0.489	<.001	8	view →
LUAD	All	All	+0.200	<.001	5	view →
CCRCC	All	III,IV	+0.110	.011	5	view →
PDAC	All	All	+0.247	.015	4	view →
COAD	Male	All	+0.141	.025	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MED18–HNSC

Open the HNSC breakdown →